GSK wins new reprieve as Hikma's generic Advair delayed again

GSK wins new reprieve as Hikma's generic Advair delayed again(Reuters) - GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug. The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura , said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well.




from Yahoo News - Latest News & Headlines http://ift.tt/2FMvd6G
via Latest News

Comments

Post a Comment

Popular posts from this blog

Facebook's latest bug exposed the private photos of 6.8 million users - The INQUIRER

Facebook's latest bug exposed the private photos of 6.8 million users    The INQUIRER After a year from hell, Facebook parties like it's 2017    The Guardian Facebook bug may have exposed users’ photos    ConsumerAffairs Bug may have exposed photos from 7 million Facebook users | WSB-TV    WSB Atlanta Use This Tool To See If Your Photos Were Exposed In Facebook's Latest Privacy Blunder    Hot Hardware View full coverage on Google News from Technology - Latest - Google News https://ift.tt/2Bs7iVW via Technology
Read more

Overwatch 2 Anime Charm Is Cheaper In Real Life Than In The Game - Kotaku

Overwatch 2 Anime Charm Is Cheaper In Real Life Than In The Game    Kotaku Blizzard Sells an Overwatch 2 Charm Cheaper in Real Life Than In-Game    IGN Real life Overwatch 2 charm costs less than it does in game    PCGamesN Overwatch 2 Fans Upset at Blizzard's Reasoning for Not Nerfing Sojourn    GameRant Overwatch 2: Keychain Costs More In-Game Than Real Life    DualShockers View Full Coverage on Google News from Technology - Latest - Google News https://ift.tt/P970ArQ via Technology
Read more